Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. The Company is initially applying its technology to develop an oral formulation of a human parathyroid hormone analog, Oral PTH (1-34), for treatment of hypoparathyroidism and osteoporosis. Entera has developed a proprietary platform technology that enables oral delivery of biologicals and large molecule drugs, which are typically delivered via injections and or other non-oral pathways. However, oral drug delivery is the easiest method for self-administering medications, offers patients greater dosing flexibility, and has the highest patient acceptance and compliance rates as compared to all other routes of drug administration. The Company employs this technology for its own pipeline products and may enter into licensing agreements with biopharma companies for application of the technology to their proprietary compounds, such as the Amgen strategic research collaboration. Source
No articles found.
Generex Biotechnology is an integrated healthcare holding company with end-to-end ...
Generex Biotechnology is an integrated healthca...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
RB is the global leading consumer health, hygiene and home company. Driven by a pu...
RB is the global leading consumer health, hygie...
Orgenesis is a vertically-integrated biopharmaceutical company with unique experti...
Orgenesis is a vertically-integrated biopharmac...
Join the National Investor Network and get the latest information with your interests in mind.